secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-07-29T23:59:59+00:00
Accession:  0000950170-22-013406
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule
--------------------------------------------------------------------------------

- Nasdaq notice dated July 25, 2022; stock bid price below $1.00 for 30 consecutive business days.
- Company has 180 calendar days, until January 23, 2023, to regain compliance.
- To cure, closing bid price must be at least $1.00 for 10 consecutive business days.
- Failure may lead to a second 180-day cure period or delisting, subject to appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000095017022013406/0000950170-22-013406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000095017022013406/ikt-20220725.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer